Literature DB >> 12889738

Use of positron emission tomography in anticancer drug development.

Eric O Aboagye1, Patricia M Price.   

Abstract

Positron emission tomography (PET) is increasingly being used in anticancer drug development. The technique is applicable to studies of drug delivery, and where specific probes are available, to provide pharmacodynamic readouts noninvasively in patients. Mathematical modeling of the imaging data enhances the quality of information that is obtained from such studies. This section provides a review of the PET methodologies that have been used for the development of new cancer therapies. Other than imaging of radiolabeled drugs, PET modeling has found extensive application in studies with 2-[11C]thymidine, [18F]fluorodeoxyglucose, H2(15)O, C15O, and receptor ligands.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12889738     DOI： 10.1023/a:1023521412787

Source DB:  PubMed          Journal:  Invest New Drugs        ISSN： 0167-6997            Impact factor:   3.850


  45 in total

1.  Pharmacokinetic analysis of 5-[18F]fluorouracil tissue concentrations measured with positron emission tomography in patients with liver metastases from colorectal adenocarcinoma.

Authors:  J Kissel; G Brix; M E Bellemann; L G Strauss; A Dimitrakopoulou-Strauss; R Port; U Haberkorn; W J Lorenz
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

2.  Human tumor fluorouracil trapping: clinical correlations of in vivo 19F nuclear magnetic resonance spectroscopy pharmacokinetics.

Authors:  C A Presant; W Wolf; M J Albright; K L Servis; R Ring; D Atkinson; R L Ong; C Wiseman; M King; D Blayney
Journal:  J Clin Oncol       Date:  1990-11       Impact factor: 44.544

3.  Modulation of fluorouracil tissue pharmacokinetics by eniluracil: in-vivo imaging of drug action.

Authors:  A Saleem; J Yap; S Osman; F Brady; B Suttle; S V Lucas; T Jones; P M Price; E O Aboagye
Journal:  Lancet       Date:  2000-06-17       Impact factor: 79.321

Review 4.  Enzymology of cancer cells (first of two parts).

Authors:  G Weber
Journal:  N Engl J Med       Date:  1977-03-03       Impact factor: 91.245

5.  Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. Generalizations.

Authors:  C S Patlak; R G Blasberg
Journal:  J Cereb Blood Flow Metab       Date:  1985-12       Impact factor: 6.200

6.  Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects.

Authors:  J Logan; J S Fowler; N D Volkow; A P Wolf; S L Dewey; D J Schlyer; R R MacGregor; R Hitzemann; B Bendriem; S J Gatley
Journal:  J Cereb Blood Flow Metab       Date:  1990-09       Impact factor: 6.200

7.  Head and neck cancer: detection of recurrence with three-dimensional principal components analysis at dynamic FDG PET.

Authors:  Y Anzai; S Minoshima; G T Wolf; R L Wahl
Journal:  Radiology       Date:  1999-07       Impact factor: 11.105

8.  Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method.

Authors:  C B Wilson; A A Lammertsma; C G McKenzie; K Sikora; T Jones
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

9.  Hypoxia response elements in the aldolase A, enolase 1, and lactate dehydrogenase A gene promoters contain essential binding sites for hypoxia-inducible factor 1.

Authors:  G L Semenza; B H Jiang; S W Leung; R Passantino; J P Concordet; P Maire; A Giallongo
Journal:  J Biol Chem       Date:  1996-12-20       Impact factor: 5.157

10.  Early evaluation of tumour metabolic response using [18F]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas.

Authors:  C S Brock; H Young; S M O'Reilly; J Matthews; S Osman; H Evans; E S Newlands; P M Price
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640
View more
  7 in total

1.  Medical imaging in new drug clinical development.

Authors:  Yi-Xiang Wang; Min Deng
Journal:  J Thorac Dis       Date:  2010-12       Impact factor: 2.895

Review 2.  Current and future use of positron emission tomography (PET) in breast cancer.

Authors:  David A Mankoff; William B Eubank
Journal:  J Mammary Gland Biol Neoplasia       Date:  2006-04       Impact factor: 2.673

Review 3.  Molecular imaging research in the outcomes era: measuring outcomes for individualized cancer therapy.

Authors:  David A Mankoff; Finbarr O'Sullivan; William E Barlow; Kenneth A Krohn
Journal:  Acad Radiol       Date:  2007-04       Impact factor: 3.173

Review 4.  Importance of quantification for the analysis of PET data in oncology: review of current methods and trends for the future.

Authors:  Giampaolo Tomasi; Federico Turkheimer; Eric Aboagye
Journal:  Mol Imaging Biol       Date:  2012-04       Impact factor: 3.488

Review 5.  Positron emission tomography imaging of small animals in anticancer drug development.

Authors:  Eric O Aboagye
Journal:  Mol Imaging Biol       Date:  2005 Jan-Feb       Impact factor: 3.488

Review 6.  Molecular imaging as a tool for translating breast cancer science.

Authors:  David A Mankoff
Journal:  Breast Cancer Res       Date:  2008-12-09       Impact factor: 6.466

7.  [18F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer.

Authors:  Rohini Sharma; Pablo Oriol Valls; Marianna Inglese; Suraiya Dubash; Michelle Chen; Hani Gabra; Ana Montes; Amarnath Challapalli; Mubarik Arshad; George Tharakan; Ed Chambers; Tom Cole; Jingky P Lozano-Kuehne; Tara D Barwick; Eric O Aboagye
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-11-21       Impact factor: 9.236
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.